Bioplatforms Australia Press Release
Australian Health Genomics Alliance
NCRIS supports Australia’s health system adopt Genomics technology
Bioplatforms Australia is committed to providing the research infrastructure required and fostering the collaboration of the best brains in genomic research to achieve life-changing beneficial outcomes for people suffering from cancer or rare diseases. Bioplatforms Australia’s contribution through the National Collaborative Research Infrastructure Strategy (NCRIS) facilitates collaborative access to big data harnessed from DNA sequencing and the bioinformatics (computational capacity, software development, data storage and management etc.) capability required to extract useful information from the data.
The Australian Genomics Health Alliance (AGHA), which brings together 47 partner organisations committed to integrating genomic medicine into healthcare across Australia, launched its research plan this year. As a co-investor with the National Health and Medical Research Council (NHMRC), Bioplatforms Australia has provided sophisticated biomolecular research infrastructure to enable this alliance. Bioplatforms Australia has further made the commitment to contribute $1M for the generation of whole genome sequencing data to support AGHA’s Cancer Flagship Projects over 2016 and 2017.
Bioplatforms Australia General Manager Andrew Gilbert said, “Personalised medicine for disease treatment and prevention is an emerging field. This requires cutting-edge infrastructure, pipelines and cross-agency collaboration to tie vast amounts of data from multiple sources together. Bioplatforms Australia facilities, supported through NCRIS, are embedded in collaborative precision medicine activities on the international, national and state levels.”
Bioplatforms Australia’s contribution to the alliance has provided infrastructure support at Garvan, Australian Genome Research Facility (AGRF), National Computational Infrastructure (NCI), Ramaciotti Centre and the Victorian Life Sciences Computation Initiative (VLSCI). Bioplatforms Australia’s investment has been further leveraged by the State Governments of NSW and Victoria, and the ACT, through the commitment of funds to establish state-based collaborations: the Melbourne Genome Health Alliance, the ACT Health Genomics Initiative and the NSW Genomics Collaborative. The critical genome sequencing infrastructure and sophisticated pipelines required by the state-based health systems to develop precision medicine will be accessed through Bioplatforms Australia facilities.
Bioinformatics pipelines developed for the Melanoma Genome Project by Bioplatforms Australia is also being used to support the broader AGHA initiative. As is the National Centre for Indigenous Genomics, which is being consulted for the AGHA. Bioplatforms Australia is an investor and research infrastructure provider for a number of other genome health alliances that feed into and extract from this initiative.
“The AGHA national initiative, supported by the state-based initiatives, will provide the roadmap for how genomics can be adopted into the health system to help clinicians better treat patients who suffer from cancer, rare diseases, paediatric disorders and so on,” said Gilbert. “Bioplatforms Australia’s role in facilitating and encouraging collaboration, and indeed further investment, delivers faster outcomes of greater value to the community.”
For more information visit: http://www.bioplatforms.com/agha/
This press release can be downloaded here: AGHA Announcement – Press Release
Andrew Gilbert | T: 02 9850 8281 | firstname.lastname@example.org
+61 0410 538 648